| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Genprex, Inc.: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer | 47 | PR Newswire | Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations
AUSTIN, Texas, May 14, 2024 /PRNewswire/ --... ► Artikel lesen | |
| 25.04. | Abzena Launches EpiScreen® 2.0, a Next Generation Immunogenicity Tool for De-Risking the Development of Complex Biologics and Bioconjugates | 315 | PR Newswire | CAMBRIDGE, England, April 25, 2024 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay... ► Artikel lesen | |
| 23.04. | INmune Bio, Inc.: INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay | 65 | GlobeNewswire (Europe) | Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's... ► Artikel lesen | |
| 01.04. | EpiVax, Inc.: Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development | 310 | PR Newswire | PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational... ► Artikel lesen | |
| 22.03. | FDA grants full approval to AbbVie/ImmunoGen drug Elahere | 4 | Seeking Alpha | ||
| 14.03. | First Wave BioPharma acquires ImmunogenX to bolster GI pipeline | 3 | Investing.com | ||
| 14.03. | First Wave BioPharma, Inc.: First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline | 99 | GlobeNewswire (Europe) | Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma... ► Artikel lesen | |
| 14.03. | First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease | 2 | Benzinga.com | ||
| 12.03. | Genprex, Inc.: Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers | 114 | PR Newswire | Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials
AUSTIN, Texas... ► Artikel lesen | |
| 29.02. | Imunon, Inc.: Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 | 177 | GlobeNewswire (Europe) | Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 22.02. | ImmunoGen, Inc. - 15-12G, Securities registration termination | 4 | SEC Filings | ||
| 22.02. | AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel | 16 | BNN Bloomberg | ||
| 21.02. | AbbVie plans to offer senior notes to fund Immunogen, Cerevel deals | 9 | Seeking Alpha | ||
| 13.02. | AbbVie concludes acquisition of ImmunoGen for $10.1bn | 20 | Pharmaceutical Technology | ||
| 13.02. | BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase | 10 | Alliance News | ||
| 13.02. | BioPharma Credit PLC - STATEMENT RE IMMUNOGEN, INC. | 1 | RNS | ||
| 12.02. | AbbVie Cuts Its Guidance on ImmunoGen Deal | 17 | Investopedia | ||
| 12.02. | AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule | 13 | FiercePharma | ||
| 12.02. | AbbVie Completes ImmunoGen Acquisition | 9 | Contract Pharma | ||
| 12.02. | NSE - ImmunoGen, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 3 | SEC Filings |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 3.598 |
| GAMESTOP | 2.557 |
| NVIDIA | 2.395 |
| NEL | 2.387 |
| TUI | 2.079 |
| BAYER | 1.358 |
| REDCARE PHARMACY | 1.276 |
| RHEINMETALL | 1.114 |
| PLUG POWER | 1.099 |
| SIEMENS ENERGY | 1.097 |
| TESLA | 974 |
| BYD | 945 |
| MERCEDES-BENZ | 902 |
| VOLKSWAGEN | 902 |
| COMMERZBANK | 900 |
| AIXTRON SE | 888 |
| DEUTSCHE LUFTHANSA | 888 |
| DEUTSCHE BANK | 800 |
| RENK GROUP | 793 |
| THYSSENKRUPP NUCERA | 714 |
| SUPER MICRO COMPUTER | 686 |
| AMC ENTERTAINMENT | 659 |
| BASF | 639 |
| THYSSENKRUPP | 628 |
| RWE | 596 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
